| News

Basel is very open to newcomers

03.06.2021

In an interview that was published in “network mag”, Novartis CEO Vas Narasimhan talks about diversity at Novartis and his positive experience of living in Basel.

Novartis
Vas Narasimhan (image: Novartis)

In 2018, Vas Narasimhan became CEO of pharmaceutical company Novartis. The American, his wife and two sons have lived in Basel for more than ten years. With “network mag”, Vas Narasimhan shared his view on diversity and inclusion and on living in Basel.

Asked about his experience of living in Switzerland, Narasimhan answers: “Nestled in the heart of Europe, I’ve found that Basel is very internationally minded and open to newcomers. This may be because it is a border town and because historically immigrants have found their way to Basel, including some of the founders of the pharmaceutical and chemical companies that have become global leaders. When you think that Novartis and our predecessor companies have been shipping goods from here for over 250 years, you realize how closely this place has been linked to the world over the past centuries. My experience here has only been positive.”

Narasimhan also told the magazine that Basel became his and his family’s home by now. He also revealed what he likes best about living in Switzerland: “Switzerland is a great place to live, and I am very happy here. The landscape is breathtaking, and there is good social and healthcare infrastructure. The overall quality of life here is very high. There’s a lot to love!”

Novartis is one of the biggest pharmaceutical companies in the world. It’s global headquarters are located in Basel. More than 104’000 employees work for Novartis around the globe. In 2020, the company had a turnover of 48.7 billion dollars and reported a net profit of 8.1 billion dollars.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Alentis secures 67 million US dollars
Basel Area Business & Innovation, Innovation, Invest

Alentis secures 67 million US dollars

The Basel-based biotechnology company Alentis Therapeutics has secured 67 million US dollars in a series B funding round. The funds...

Read More
RocketVax secures partners for coronavirus vaccine in Basel
Basel Area Business & Innovation, Innovation

RocketVax secures partners for coronavirus vaccine in Basel

RocketVax has found cooperation partners for the development of its innovative coronavirus vaccine. The University Hospital of Basel, the University...

Read More
Bright Peak secures investment of 107 million dollars
Basel Area Business & Innovation, Innovation, Invest

Bright Peak secures investment of 107 million dollars

Bright Peak has raised a total of 107 million US dollars as part of a financing round. The biotechnology firm...

Read More
LCB lands major contract
Basel Area Business & Innovation, Innovation, Invest

LCB lands major contract

LCB Sàrl is active in the areas of Human Machine Interface as well as software and electronics development. The company...

Read More
Scailyte now calls Basel home
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Scailyte now calls Basel home

The biotechnology firm Scailyte is now installed at the Novartis Campus of Switzerland Innovation Park Basel Area. Scailyte develops solutions...

Read More
1 2 3 45

Do you have a question? We'd like to hear from you.